Clinical trial · Observational
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
A Study to Evaluate Patient and Physician Benefit/ Risk Preferences for Treatment of Metastatic Prostate Cancer (mPC) in Hong Kong: a Discrete Choice Experiment
NCT05761093CI-TRIAL-00089353recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to examine the preference weightings in term of risk/ benefit attributes of treatment in physician and prostate cancer patients from different stages of disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Patient preferences for treatment attributes in prostate cancer from different stages of disease
- timeFrame
- 15 minutes (Once through survey)
- description
- Derived from discrete choice experiment
- measure
- The Preference weighting from Physicians involved in the treatment of prostate cancer in term of risk/benefit attributes of treatment.
- timeFrame
- 15 minutes (Once through survey)
- description
- Derived from discrete choice experiment.
Secondary outcomes (3)
- measure
- To examine the effect of socio-economic status on preference weighing
- timeFrame
- 15 minutes (Once through survey)
- description
- Derived from discrete choice experiment
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * aged 18 years or older, * diagnosis of metastatic prostate cancer within 5 years, * able to read and write, * accepting and signing the informed consent Exclusion Criteria: * if patients are unable to complete the survey by themselves due to physical or psychological reasons, * deemed ineligible by treating physicians if patients are unable to complete the survey by themselves due to physical or psychological reasons, * deemed ineligible by treating physicians
References
Publications (8)
- BACKGROUNDSartor O, de Bono JS. Metastatic Prostate Cancer. N Engl J Med. 2018 Feb 15;378(7):645-657. doi: 10.1056/NEJMra1701695. Epub 2018 Feb 7. No abstract available. PMID 29412780
- BACKGROUNDFeldman-Stewart D, Brundage MD, Van Manen L, Svenson O. Patient-focussed decision-making in early-stage prostate cancer: insights from a cognitively based decision aid. Health Expect. 2004 Jun;7(2):126-41. doi: 10.1111/j.1369-7625.2004.00271.x. PMID 15117387
- BACKGROUNDAning JJ, Wassersug RJ, Goldenberg SL. Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Curr Oncol. 2012 Dec;19(Suppl 3):S37-44. doi: 10.3747/co.19.1287. PMID 23355792
- BACKGROUNDUemura H, Matsubara N, Kimura G, Yamaguchi A, Ledesma DA, DiBonaventura M, Mohamed AF, Basurto E, McKinnon I, Wang E, Concialdi K, Narimatsu A, Aitoku Y. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. BMC Urol. 2016 Nov 4;16(1):63. doi: 10.1186/s12894-016-0182-2. PMID 27814714
- BACKGROUNDHauber AB, Arellano J, Qian Y, Gonzalez JM, Posner JD, Mohamed AF, Gatta F, Tombal B, Body JJ. Patient preferences for treatments to delay bone metastases. Prostate. 2014 Nov;74(15):1488-97. doi: 10.1002/pros.22865. Epub 2014 Aug 17. PMID 25132622
- BACKGROUNDRyan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000 Jun 3;320(7248):1530-3. doi: 10.1136/bmj.320.7248.1530. No abstract available. PMID 10834905
- BACKGROUNDFizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.